These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1954381)

  • 1. Interleukin-6 gene expression in Castleman's disease.
    Leger-Ravet MB; Peuchmaur M; Devergne O; Audouin J; Raphael M; Van Damme J; Galanaud P; Diebold J; Emilie D
    Blood; 1991 Dec; 78(11):2923-30. PubMed ID: 1954381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J; Maruyama I
    Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of interleukin-6 in Castleman's disease.
    Hsu SM; Waldron JA; Xie SS; Barlogie B
    Hum Pathol; 1993 Aug; 24(8):833-9. PubMed ID: 8375854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
    Nishi J; Arimura K; Utsunomiya A; Yonezawa S; Kawakami K; Maeno N; Ijichi O; Ikarimoto N; Nakata M; Kitajima I; Fukushige T; Takamatsu H; Miyata K; Maruyama I
    Br J Haematol; 1999 Mar; 104(3):482-5. PubMed ID: 10086783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.
    Sato Y; Kojima M; Takata K; Morito T; Asaoku H; Takeuchi T; Mizobuchi K; Fujihara M; Kuraoka K; Nakai T; Ichimura K; Tanaka T; Tamura M; Nishikawa Y; Yoshino T
    Mod Pathol; 2009 Apr; 22(4):589-99. PubMed ID: 19270642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castleman's disease.
    Palestro G; Turrini F; Pagano M; Chiusa L
    Adv Clin Path; 1999; 3(1-2):11-22. PubMed ID: 10655569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome.
    Gherardi RK; Bélec L; Fromont G; Divine M; Malapert D; Gaulard P; Degos JD
    Blood; 1994 May; 83(9):2587-93. PubMed ID: 8167341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies.
    Menke DM; Tiemann M; Camoriano JK; Chang SF; Madan A; Chow M; Habermann TM; Parwaresch R
    Am J Clin Pathol; 1996 Mar; 105(3):268-76. PubMed ID: 8602606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
    Yoshizaki K; Matsuda T; Nishimoto N; Kuritani T; Taeho L; Aozasa K; Nakahata T; Kawai H; Tagoh H; Komori T
    Blood; 1989 Sep; 74(4):1360-7. PubMed ID: 2788466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ornithine decarboxylase gene expression in Castleman's disease.
    Malaguarnera L; Pilastro MR; Vicari L; Di Marco R; Malaguarnera M; Messina A
    J Mol Med (Berl); 1999 Nov; 77(11):798-803. PubMed ID: 10619440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.
    Momoi A; Kojima M; Sakai T; Ajiro J; Isahai N; Nagai K; Aoki S
    Int J Hematol; 2013 Feb; 97(2):275-9. PubMed ID: 23359301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
    Kinney MC; Hummell DS; Villiger PM; Hourigan A; Rollins-Smith L; Glick AD; Lawton AR
    J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5.
    Ishii T; Tatekawa T; Koseto M; Ishii M; Kobayashi H; Koike M; Fujii T; Saeki Y
    Eur J Haematol; 2003 Feb; 70(2):115-8. PubMed ID: 12581193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease.
    Ishiyama T; Nakamura S; Akimoto Y; Koike M; Tomoyasu S; Tsuruoka N; Murata Y; Sato T; Wakabayashi Y; Chiba S
    Br J Haematol; 1994 Mar; 86(3):483-9. PubMed ID: 8043430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice.
    Screpanti I; Musiani P; Bellavia D; Cappelletti M; Aiello FB; Maroder M; Frati L; Modesti A; Gulino A; Poli V
    J Exp Med; 1996 Oct; 184(4):1561-6. PubMed ID: 8879230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes.
    Emilie D; Peuchmaur M; Maillot MC; Crevon MC; Brousse N; Delfraissy JF; Dormont J; Galanaud P
    J Clin Invest; 1990 Jul; 86(1):148-59. PubMed ID: 2114424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.
    Parravicini C; Corbellino M; Paulli M; Magrini U; Lazzarino M; Moore PS; Chang Y
    Am J Pathol; 1997 Dec; 151(6):1517-22. PubMed ID: 9403701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Utility of Interleukin-6 Expression by Immunohistochemistry in Differentiating Castleman Disease Subtypes and Reactive Lymphadenopathies.
    Post GR; Bell RC; Rjoop A; Lobo RH; Yuan Y; Post SR
    Ann Clin Lab Sci; 2016 Sep; 46(5):474-9. PubMed ID: 27650613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
    Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
    Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of interleukin-6 and its clinicopathological significance in Castleman's disease].
    Lai YM; Li M; Liu CL; Huang X; Yu GH; Wang XY; Sun L; Chen J; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):404-8. PubMed ID: 23688750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.